These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35811776)

  • 1. Comprehensive Analysis of the E2F Transcription Factor Family in Human Lung Adenocarcinoma.
    Wang Q; Liu J; Cheang I; Li J; Chen T; Li Y; Yu B
    Int J Gen Med; 2022; 15():5973-5984. PubMed ID: 35811776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma.
    Lin S; Yu X; Yan H; Xu Y; Ma K; Wang X; Liu Y; Xie A; Yu Z
    Medicine (Baltimore); 2024 Jan; 103(3):e34342. PubMed ID: 38241554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Expression of RTN1 in Lung Adenocarcinoma and 
Its Effect on Immune Microenvironment].
    Zhu S; Zu L; Xu S
    Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic role of E2F transcription factors in high-grade glioma.
    Yu H; Li Z; Wang M
    CNS Neurosci Ther; 2020 Jul; 26(7):741-753. PubMed ID: 32064771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting.
    Jiao L; Tao Y; Ding H; Wu F; Liu Y; Li C; Li F
    3 Biotech; 2024 Sep; 14(9):215. PubMed ID: 39220827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Analysis of E2F Expression and Its Relation in Colorectal Cancer Prognosis.
    Xu Z; Qu H; Ren Y; Gong Z; Ri HJ; Zhang F; Shao S; Chen X; Chen X
    Int J Gen Med; 2022; 15():4849-4870. PubMed ID: 35585998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of E2F transcription factors 7: An independent predictor of poor prognosis in patients with lung adenocarcinoma.
    Zhang Y; Lyu L; Wang W; Zhang L
    Medicine (Baltimore); 2022 Aug; 101(33):e29253. PubMed ID: 35984189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of E2F7 in immunotherapy efficacy for lung adenocarcinoma: An observational study.
    Cui H; Li H; Liu J; Zhao P; Liu Y; Zhong R; Li R; Cheng Y
    Medicine (Baltimore); 2024 Jun; 103(25):e38574. PubMed ID: 38905387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.
    Wu YJ; Nai AT; He GC; Xiao F; Li ZM; Tang SY; Liu YP; Ai XH
    World J Surg Oncol; 2021 Sep; 19(1):274. PubMed ID: 34517904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of ALG3 as a potential prognostic biomarker in lung adenocarcinoma.
    Yuan Y; Xie B; Guo D; Liu C; Jiang G; Lai G; Zhang Y; Hu X; Wu Z; Zheng R; Huang L
    Heliyon; 2023 Jul; 9(7):e18065. PubMed ID: 37539167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma.
    Li L; Li J
    Front Oncol; 2023; 13():1128785. PubMed ID: 36959799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bioinformatics analysis for diagnostic roles of the
    Li J; Wang H; Cao F; Cheng Y
    J Gastrointest Oncol; 2022 Oct; 13(5):2115-2131. PubMed ID: 36388667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma.
    Liu XS; Gao Y; Liu C; Chen XQ; Zhou LM; Yang JW; Kui XY; Pei ZJ
    Front Oncol; 2020; 10():606735. PubMed ID: 33604289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Values of E2F1/2 Transcriptional Expressions in Chromophobe Renal Cell Carcinoma Patients: Evidence from Bioinformatics Analysis.
    Hu D; Meng N; Lou X; Li Z; Teng Y; Tu B; Zou Y; Wang F
    Int J Gen Med; 2021; 14():3593-3609. PubMed ID: 34295182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of GNPNAT1 Predicts Poor Prognosis and Correlates With Immune Infiltration in Lung Adenocarcinoma.
    Liu W; Jiang K; Wang J; Mei T; Zhao M; Huang D
    Front Mol Biosci; 2021; 8():605754. PubMed ID: 33842535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent Prognostic Potential of GNPNAT1 in Lung Adenocarcinoma.
    Zheng X; Li Y; Ma C; Zhang J; Zhang Y; Fu Z; Luo H
    Biomed Res Int; 2020; 2020():8851437. PubMed ID: 33178836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of the functional and prognostic value of E2F transcription factors in human prostate cancer through data mining and experimental validation.
    Wang D; Tang W; Zhang P; Liu Z; Lyu F; Xiao Y; Ni D; Zhang P
    Transl Cancer Res; 2021 Dec; 10(12):5095-5109. PubMed ID: 35116361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.